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Abstract
The outlook for elimination of the scourge of cervical cancer is bright, because we now 
have the tools to achieve this goal. In recent years human papillomavirus (HPV) vac-
cination in high-income countries has resulted in dramatic decreases in HPV infection 
and associated cervical disease. If all countries with a substantial burden of disease 
introduce the vaccine nationally, we can protect the vast majority of women and girls 
most at risk. For women who are beyond the vaccination target age, progress has been 
made in screening and treatment for cervical precancer, but we must accelerate this 
momentum to reduce incidence and mortality worldwide to the very low rates found 
in wealthier countries. Human and financial resources must be increased and directed 
to programs that follow best practices and reach all women, including the marginalized 
or dis advantaged. Seven key actions are recommended. Now is the time for action at 
national, regional, and global levels.
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United Nations Secretary- General Ban Ki-moon’s 2016 call to eliminate 
cervical cancer was a critical moment showing how far we have come—
and how far we still have to go.1 Elimination of this scourge is an excit-
ing, ambitious, and laudable goal. The first steps toward elimination 
are embodied in the 2013–2020 Global Action Plan for the Prevention 
and Control of Noncommunicable Diseases.2 The outlook for cervical 
cancer prevention is bright—we know what to do and we have the tools 
to do it.3 The papers in this Supplement of the IJGO make that clear.
Of the 640 000 cancer cases caused each year by the human pap-
illomavirus (HPV), 89% affect women, and cervical cancer accounts 
for 82% of the total.4 Preventing cervical cancer does not require 
difficult changes in behaviors developed over a lifetime, such as eat-
ing fewer fatty foods or quitting cigarettes. Like liver cancer, cervical 
cancer is preventable with safe and effective vaccines. Furthermore, 
screening and preventive treatment (for cervical precancer) prevents 
the development of invasive cancer. So we are fortunate to have two 
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prophylactic strategies to deploy—vaccination for young adolescents 
and screening and preventive treatment for adult women.
In the 10 years since HPV vaccines were introduced in high- 
income countries, we have seen dramatic decreases in HPV infection 
and associated cervical disease among vaccinated populations, and 
even among the unvaccinated (through herd immunity, where cover-
age is high). As coverage increases, we anticipate significant impact 
from the vaccine, since it can protect against 70%–90% of cervical 
cancer and several other HPV- related cancers. If all countries with a 
substantial burden of disease introduce the vaccine nationally, we can 
go a long way toward protecting the vast majority of those women 
and girls most at risk. Unfortunately, only about 3% of eligible girls 
worldwide are estimated to have been vaccinated against HPV so far, 
despite that more than 80 countries have officially incorporated the 
vaccine into their national immunization programs.5 Countries with 
high HIV prevalence, which could benefit most from HPV vaccination 
because of the increased risk for cervical cancer among HIV- positive 
women,6 are among those with very low coverage rates to date.
There also is good news for women who are beyond vaccination 
target age when HPV vaccines become available in their communities. 
New, relatively simple and affordable cervical cancer screening and pre-
ventive treatment strategies are being adopted by many countries that 
previously had no such programs.7 In most cases, treatment of women 
with precancer is relatively low cost, especially compared to the cost of 
invasive cancer treatment (which, in far too many cases, is not widely 
accessible). More women are now being screened and treated than 
ever before, but global coverage, again, is estimated to be very low.
While this Supplement focuses on prevention of disease, it should 
be noted that expanding services to treat invasive cancer could also 
save many lives.
In spite of low coverage with vaccination and screening/preventive 
treatment, there is positive momentum and cause for optimism. In just 
the past few years:
1. The Indian government organized a high-level meeting on moving 
the cervical cancer screening and control agenda forward—notable 
in a country with 25% of global cervical cancer deaths;
2. Gavi, the Vaccine Alliance, approved many new countries for HPV 
vaccine support, including populous Indonesia;
3. In Africa, the WHO supported 18 countries in piloting HPV vacci-
nation, as well as introducing HPV immunization nationwide in six 
others;
4. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
released a comprehensive report on leveraging the synergies 
between HIV, HPV, and cervical cancer,8 and the 2016 UN General 
Assembly Political Declaration on HIV and AIDS called for integra-
tion of HIV and cervical cancer services9;
5. The annual UNAIDS-led Global AIDS Monitoring report (GAM) will 
include two new indicators on HPV vaccination and cervical cancer 
screening for HIV-positive women beginning in 2017;
6. Harvard and the American Cancer Society completed ground-
breaking modeling of the cost of cervical cancer prevention 
globally10;
7. Both The New England Journal of Medicine3 and The Lancet11 pub-
lished noteworthy papers highlighting the importance of cervical 
cancer as an equity issue and the urgent need for cervical cancer 
prevention to expand from pilot projects to national scale.
To accelerate this momentum and reduce cervical cancer incidence 
and mortality worldwide to the very low rates found in wealthier coun-
tries, it is essential that human and financial resources be significantly 
increased and directed to cervical cancer programs that follow best 
practices and reach all women, including those who are marginalized 
or disadvantaged. This requires strategic partnerships. A key focus of 
one coalition, the Cervical Cancer Prevention Initiative,12 is to broaden 
the stakeholder base, engaging organizations for which cancer has 
not traditionally been a focus—groups like Every Woman Every Child, 
The US President’s Emergency Plan for AIDS Relief (PEPFAR), Rotary 
International, UNAIDS, and Women Deliver. Furthermore, building on 
lessons learned from HIV activism and advocacy, civil society—in par-
ticular, networks of women living with HIV and the women’s rights 
movement—have a critical role to play in cervical cancer prevention 
and treatment. The coalition also is seeking common ground with 
funding mechanisms outside typical bilateral or foundation channels—
such as the Global Fund and the Global Financing Facility. Another 
exciting development is the launch of the United Nations Global Joint 
Programme on Cervical Cancer with participation from WHO, IAEA, 
IARC, UNAIDS, UNFPA, UNICEF, and UN Women.13 Just getting 
started as this Supplement goes to press, this partnership also seeks 
to scale up prevention, screening, and treatment, with a focus on low- 
and lower- middle-income countries.
Many leaders see cervical cancer prevention and control as 
a human rights issue. They are quick to point out that progress in 
prevention will contribute not only to the Sustainable Development 
Goals for good health and well- being, but also to goals that seek to 
increase gender equity.11 Women play a critical role in sustainable 
development. When they are able to reach their full potential, women 
contribute to thriving families, build more resilient communities, are 
stalwart stewards of the environment, and are powerful drivers of 
economic development. It will be difficult for countries to achieve 
their national aspirations without addressing diseases that deprive 
them of the talents and contributions of women in the prime of their 
lives.
At this point in time, scaling up cervical cancer prevention is not 
a question of waiting for new information or delaying until ideal tech-
nologies come to market. It is a question of motivation, commitment, 
and passion for improving women’s health outcomes. It is a question 
of ensuring that the women who benefit from vastly improved obstet-
ric care or HIV management also have access to screening and will not 
be torn from their families a decade or two later as victims of cervical 
cancer. It is a question of ensuring that girls everywhere are protected 
from HPV infection through vaccination.
Overall, we need to:
1. Harness the tools and best practices we already have in hand 
and scale them up into national programs;
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2. Seek synergies with other primary healthcare services, including 
integration with HIV services;
3. Ensure seamless linkages between screening and treatment of pre-
cancer so that no woman is lost to follow-up;
4. Negotiate affordable vaccine pricing for non-Gavi countries and 
develop innovative financing mechanisms for essential screening 
and precancer treatment supplies, equipment, and training;
5. Work with all relevant stakeholders to ensure public and policy 
maker confidence in HPV vaccination and new screening and pre-
ventive treatment modalities in order to achieve maximal vaccine 
and screening coverage;
6. Capture reliable data on cervical cancer prevention services in 
national health information systems so that progress against essen-
tial indicators can be tracked nationally and globally and so that 
resources can be allocated where they are needed most;
7. Where resources permit, improve access to definitive cancer treat-
ment and effective palliative care for those who did not benefit 
from prevention efforts.
The end of cervical cancer is now in sight. With funding already avail-
able to vaccinate an additional 40 million girls by 2020, we have a huge 
opportunity to reduce the number of women dying from cervical cancer. 
Similar resources must also be mobilized for screening. We call on the 
new UN Secretary- General, donors, and all national leaders—particu-
larly those in low- and middle- income countries—to support this call for 
action, to drive national political will, and encourage increased UN coor-
dination and collaboration. Now is the time to prevent the unrelenting 
pain and isolating stigma of cervical cancer. Now is the time for action at 
national, regional, and global levels. We can do this and we must.
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